Clinical trial
A Phase II Pilot Study of Bortezomib (PS-341, Velcade) Combined With Reinduction Chemotherapy in Children and Young Adults With Recurrent, Refractory or Secondary Acute Myeloid Leukemia
NCT00666588 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Pilot Study of Bortezomib (PS-341, Velcade) Combined With Reinduction Chemotherapy in Children and Young Adults With Recurrent, Refractory or Secondary Acute Myeloid Leukemia
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2008
- Completion date
- December 31, 2012
- Enrollment
- 52 (actual)
- Sites
- 82
Conditions
As the registry lists them; a condition with its own page is linked.
adult acute monoblastic leukemia (m5a), adult acute monocytic leukemia (m5b), adult acute myeloblastic leukemia with maturation (m2), adult acute myeloblastic leukemia without maturation (m1), adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myelomonocytic leukemia (m4), childhood acute basophilic leukemia, childhood acute eosinophilic leukemia, childhood acute erythroleukemia (m6), childhood acute megakaryocytic leukemia (m7), childhood acute minimally differentiated myeloid leukemia (m0), childhood acute monoblastic leukemia (m5a), childhood acute monocytic leukemia (m5b), childhood acute myeloblastic leukemia with maturation (m2), childhood acute myeloblastic leukemia without maturation (m1), childhood acute myelomonocytic leukemia (m4), recurrent adult acute myeloid leukemia, recurrent childhood acute myeloid leukemia, secondary acute myeloid leukemia